Danone has introduced a new beverage under its Oikos brand, aimed at U.S. consumers who use GLP-1 weight loss medications such as Wegovy and Ozempic. The product, Oikos Fusion, is designed to help address the muscle loss often experienced by patients on these drugs, which include Zepbound and are sometimes referred to as “the shot.”
According to Danone, GLP-1 users can lose as much as one-fifth of their weight from muscle rather than fat, a concern that has prompted dietary adjustments such as increasing protein intake. Oikos Fusion contains vitamin D and whey protein, which the company says support muscle building and maintenance.
Danone is among several food companies developing products tailored to the growing market of GLP-1 users. Conagra has labeled some Healthy Choice frozen meals as “GLP-1 friendly,” while Nestlé has introduced its Vital Pursuit line, which offers smaller portions with higher protein content.
The Paris-based company previously launched other high-protein Oikos products, including smoothies competing with Coca-Cola’s Fairlife and entering the protein shake segment with Oikos Protein Shakes earlier this year. These efforts contributed to more than 2% sales growth in North America in the second quarter, with Oikos being a significant driver.
“This is a brand that has been growing at a rapid pace in the marketplace and strategically expanding,” said Rafael Acevedo, president of yogurt at Danone North America. He added that GLP-1 users represent a central focus for the new launch.
Oikos Fusion’s formula contains a patented mix of whey, leucine, and vitamin D to promote muscle mass and support digestive health. Each 7-ounce bottle provides 23 grams of complete protein, 5 grams of prebiotic fiber, and vitamins B3 and B12 to aid energy conversion. The drink will be offered in strawberry, mixed berry, and vanilla flavors.
Danone began developing Oikos Fusion a year ago, using ingredient formulations already present in its specialized nutrition business to shorten development time and reduce costs. The company determined that combining 2-3 grams of leucine with adequate complete protein and vitamin D can stimulate muscle synthesis, particularly when supported by balanced nutrition and exercise.
Initially, Oikos Fusion will be available at Walmart for $2.12 per bottle, with a national rollout scheduled for October to Target, Kroger, and Wakefern. While the product targets the estimated 10% of U.S. consumers who have used GLP-1 drugs, it is also positioned for a broader audience seeking to maintain muscle and improve gut health.
Oikos Fusion’s debut follows Oikos’ 40% increase in retail sales in 2024, pushing the brand past $1 billion in annual sales for the first time. Danone opted to release the drink under the established Oikos label to align with its existing high-protein identity.
Acevedo said the product represents “a one-of-a-kind opportunity” to meet the nutritional needs of consumers on GLP-1 medications while expanding the brand’s role in functional, high-protein dairy offerings.
